 |
| |
 R&D Innovation & Strategies –Integrated Strategies To Over Come Pitfalls, Enhance Drug Discovery, Overcome Attrition & New Prediction Tools That Drive Clear Decision Making.
Focused Sirna Screens In Disease Based Assays - The Fast Track To A Target
Non-Invasive, Label-Free Assays - Getting the Most Out of your Targets and a Handle on Off-Target Effects
In Silico Innovation To Solve Drug Discovery – In-Silico Data, Data Mining, Predictive Modeling,
Exploring the impact & success rate of HTS Compound Library Screening.
Partnerships, Alliances & Outsourcing –Successful Partnerships, Managing Alliances, Balancing Conflicting Interests, Biotech Technology Platforms
Intergration of technologies & applications to bridge the gap between discovery, validation & development
How do you create intelligence from all this data, both structured and unstructured, across the entire value chain?
Streamline data processes and integration whilst improving early decision making and lowering attrition through the benefit of developing a dynamic workflows and an efficient infrastructure.
“An innovative approach”-lean/ 6-sigma efforts and organisational structures supporting lead optimisation."
Alternative cost effective screening methods and techniques to strengthen assay effectively. Bringing in-vitro screening for HTS, hit optimisation & lead optimisation together.
|
|
|
 |
|
|
|
|
|
|
|
|
| |
 |
Dr. Simon Fredriksson
Chief Scientific Officer
Olink Bioscience
Dr. Fredriksson is the Chief Scientific Officer at Olink Bioscience (Uppsala, Sweden) and has been a key figure in inventing and developing the proximity ligation assay for protein detection. He spent four years at Stanford University implementing PLA into a sensitive high throughput cancer biomarker research tool.
He is a cofounder and board member of Olink Bioscience focused on the commercialization of the in situ and in solution PLA technology and coordinates an EU-funded biomarker project. |
|
 |
|
|
|
|
| |
 |
Dr. Frank Brown
VP and CSO
Acclerys
Dr. Brown is presently VP and CSO for Acclerys. He has an impressive background in the Pharmaceutical industry in the field of Computational Science and Informatics. He has spent the last 20 years of his career innovating new scientific methods and applying them in commercial pharmaceutical enterprises. From 1997 to 2006, Dr. Brown held positions of increasing responsibility at Johnson & Johnson, one of the world’s largest Pharmaceutical companies, and, most recently, was a Senior Research Fellow within the Office of the CIO.
Dr. Brown received his Ph.D. in Physical Organic Chemistry from the University of Pittsburgh under the direction of Ken Houk and did post doctoral studies in Biophysics at the University of California, San Francisco under the direction of Peter Kollman. He currently serves as an Adjunct Associate Professor at the University of North Carolina, Chapel Hill’s School of Pharmacy - Division of Medicinal Chemistry where he lectures on Molecular Modeling and Drug Design. Dr. Brown is a recognized industry expert having published over 50 peer-reviewed papers, delivered over 50 invited lectures, and is the named holder of two patents. He has been actively involved with a number of both scientific journals and professional magazines and has served on a number of associated editorial boards. Additionally, Dr. Brown has served on the funding committee for the National Institute of Heath and is the past Chairman of American Chemical Society’s “Computers in Chemistry”. He is also recognized as the person who first defined Chemoinformatics and coined the word. |
|
|
|
|
|
|
| |
 |
Tony Wood
Vice President, Head of Worldwide Medicinal Chemistry,
Pfizer Global Research & Development
Tony is currently Head of Worldwide Medicinal Chemistry for PGRD. He was Head of Chemistry and Exploratory Medicinal Sciences at the PGRD Sandwich Laboratories from Feb 2007 until December 2008 and Head of Chemistry in Sandwich from April 2004. Prior to this he had responsibility for Discovery Chemistry projects in the Anti-Infectives, Asthma and Respiratory, and Pain Therapeutics groups at Sandwich.
Tony joined Pfizer as a Scientist in the Department of Discovery Chemistry at Sandwich in 1992. Over the period of the next 8 years he made a number of contributions to the delivery of development candidates in various projects from within the Sexual Health, Urology, and Gastrointestinal Therapeutic Areas. He was appointed to the post of Manager in 1999 with responsibility for Anti-Infectives Chemistry and played a leading role in the discovery of Maraviroc for which he was awarded the RSC Malcolm Campbell Prize in 2005 and the ACS Heroes of Chemistry Prize in 2008 and was a co-recipient of Prix Galien and Scrip Awards in 2008. After, a short period leading Anti-Infectives Chemistry and the Sandwich Library Design and Production Group, Tony was appointed to the post of Director in 2001 before assuming greater responsibility for the Sandwich Chemistry portfolio in 2002 with consequent promotion to Group Director.
Tony received his BSc in 1987 and PhD in 1990 in chemistry from Newcastle University before completing post-doctoral studies with Professor Steven Ley, FRS at Imperial College in London.
Tony has active interests in many areas of medicinal chemistry and has held positions on a number of UK funding council review boards such as the BBSRC and EPSRC as well as regularly reviewing scientific publications in this area. He was editor of volume 41 of Annual Reports in Medicinal Chemistry in 2006. Tony is an author or inventor on over 40 scientific publications and patents and has given invited lectures at a number of International Conferences on Medicinal Chemistry. Tony is also a visiting Professor at the University of Newcastle Upon Tyne. |
|
|
|
|
|
|
|
| |
 |
Dr. Michael Rotte MD
Global Head BMD Office
Novartis Pharma AG
BioMarker Development / TS
Dr. Michael Rotte’s Role involves Global strategy, budget, EGM, technologies: imaging, genomics, genetics, assay development, proteomics, metabonomics.
Past Positions,
• Consultant for Neurology at Otto von Guericke University
• Consultant for Sleep Medicine at Otto von Guericke University
Education
• Otto-von-Guericke-Universität Magdeburg
• Harvard University
• Otto-von-Guericke-Universität Magdebur |
|
|
|
|
|
|
|
|
| |
 |
Martin D. Leach, Ph.D.
Executive Director, MRL IT for Discovery & Preclinical Sciences
At Merck & Co., I lead IT for Discovery & Preclinical Sciences (DPS) working with leadership in DPS research groups to develop and manage a portfolio of research applications, systems and high performance computing infrastructure to support biomarker research and target ID up to first clinical studies.
Prior to Merck, my work at Booz Allen was working with the partnership to establish and build out the pharma & life sciences IT strategy practice. This spanned the entire pharma value chain with projects such as post-merger integration, IT strategy, informatics strategy, research organizational change and design.
My work at CuraGen also spanned the entire pharma research and development continuum and included informatics strategy, design, implementation, support, and integration across basic research, pre-clinical, development, clinical, and regulatory functions. While at CuraGen, my responsibilities also included corporate IT and some support of 454 (now part of Roche). My training is in cellular & molecular biology, biochemistry, neuroscience and I have a Ph.D. in molecular pharmacology from Boston University School of Medicine. With over 15 years of expertise in IT and informatics my goal is to provide scientists greater access and integration of all forms of information to expedite research, and inject technology innovation into the discovery processes. |
|
|
|
|
|
|
